Carleton BC - Search Results

1

Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions.

Amstutz U, Shear NH, Rieder MJ, Hwang S, Fung V, Nakamura H, Connolly MB, Ito S, Carleton BC; CPNDS clinical recommendation group. Amstutz U, et al. Among authors: carleton bc. Epilepsia. 2014 Apr;55(4):496-506. doi: 10.1111/epi.12564. Epub 2014 Mar 5. Epilepsia. 2014. PMID: 24597466 Free article. Review.

2

Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy.

Ross CJ, Katzov-Eckert H, Dubé MP, Brooks B, Rassekh SR, Barhdadi A, Feroz-Zada Y, Visscher H, Brown AM, Rieder MJ, Rogers PC, Phillips MS, Carleton BC, Hayden MR; CPNDS Consortium. Ross CJ, et al. Among authors: carleton bc. Nat Genet. 2009 Dec;41(12):1345-9. doi: 10.1038/ng.478. Epub 2009 Nov 8. Nat Genet. 2009. PMID: 19898482

3

Predictive genotype.

Ito S, Carleton BC. Ito S, et al. Among authors: carleton bc. CMAJ. 2010 May 18;182(8):804. doi: 10.1503/cmaj.110-2061. CMAJ. 2010. PMID: 20479057 Free PMC article. No abstract available.

4

The Canadian Pharmacogenomics Network for Drug Safety: a model for safety pharmacology.

Ross CJ, Visscher H, Sistonen J, Brunham LR, Pussegoda K, Loo TT, Rieder MJ, Koren G, Carleton BC, Hayden MR; CPNDS Consortium. Ross CJ, et al. Among authors: carleton bc. Thyroid. 2010 Jul;20(7):681-7. doi: 10.1089/thy.2010.1642. Thyroid. 2010. PMID: 20578893 Review.

5

Pharmacogenomics of cardiovascular drugs and adverse effects in pediatrics.

Visscher H, Amstutz U, Sistonen J, Ross CJ, Hayden MR, Carleton BC. Visscher H, et al. Among authors: carleton bc. J Cardiovasc Pharmacol. 2011 Sep;58(3):228-39. doi: 10.1097/FJC.0b013e3182163b82. J Cardiovasc Pharmacol. 2011. PMID: 21386709 Review.

6

Cutaneous adverse drug reactions in children: an analysis of reports from the Canadian Pharmacogenomics Network for Drug Safety (CPNDS).

Castro-Pastrana LI, Ghannadan R, Rieder MJ, Dahlke E, Hayden M, Carleton B. Castro-Pastrana LI, et al. J Popul Ther Clin Pharmacol. 2011;18:e106-20. Epub 2011 Mar 21. J Popul Ther Clin Pharmacol. 2011. PMID: 21467602

7

A systematic review of treatment of drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in children.

Del Pozzo-Magana BR, Lazo-Langner A, Carleton B, Castro-Pastrana LI, Rieder MJ. Del Pozzo-Magana BR, et al. J Popul Ther Clin Pharmacol. 2011;18:e121-33. Epub 2011 Mar 21. J Popul Ther Clin Pharmacol. 2011. PMID: 21467603 Review.

8

Pharmacogenetic testing: time for clinical practice guidelines.

Amstutz U, Carleton BC. Amstutz U, et al. Among authors: carleton bc. Clin Pharmacol Ther. 2011 Jun;89(6):924-7. doi: 10.1038/clpt.2011.18. Epub 2011 Apr 20. Clin Pharmacol Ther. 2011. PMID: 21508939 Review. No abstract available.

9

Phenotype standardization for immune-mediated drug-induced skin injury.

Pirmohamed M, Friedmann PS, Molokhia M, Loke YK, Smith C, Phillips E, La Grenade L, Carleton B, Papaluca-Amati M, Demoly P, Shear NH. Pirmohamed M, et al. Clin Pharmacol Ther. 2011 Jun;89(6):896-901. doi: 10.1038/clpt.2011.79. Epub 2011 May 11. Clin Pharmacol Ther. 2011. PMID: 21562486 Review.

10

Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children.

Visscher H, Ross CJ, Rassekh SR, Barhdadi A, Dubé MP, Al-Saloos H, Sandor GS, Caron HN, van Dalen EC, Kremer LC, van der Pal HJ, Brown AM, Rogers PC, Phillips MS, Rieder MJ, Carleton BC, Hayden MR; Canadian Pharmacogenomics Network for Drug Safety Consortium. Visscher H, et al. Among authors: carleton bc. J Clin Oncol. 2012 May 1;30(13):1422-8. doi: 10.1200/JCO.2010.34.3467. Epub 2011 Sep 6. J Clin Oncol. 2012. PMID: 21900104

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

265 results

Search Page